Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6788718 | 1.00 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL6910107 | 1.00 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL4425848 | 1.00 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL4430265 | 0.95 | HCRTR1 (0.91) | HCRTR1HCRTR2 | |
| SCHEMBL6786999 | 0.95 | HCRTR1 (0.90) | HCRTR1HCRTR2 | |
| SCHEMBL5210937 | 0.95 | HCRTR1 (0.90) | HCRTR1HCRTR2 | |
| SCHEMBL4430693 | 0.95 | HCRTR1 (0.90) | HCRTR1HCRTR2 | |
| SCHEMBL5208359 | 0.95 | HCRTR1 (0.90) | HCRTR1HCRTR2 | |
| SCHEMBL6789122 | 0.95 | HCRTR1 (0.90) | HCRTR1HCRTR2 | |
| SCHEMBL5211251 | 0.95 | HCRTR1 (0.90) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6703392-B2 | OREXIN RECEPTOR ANTAGONISTS FOR OBESITY OR SLEEPING DISORDER TREATMENT | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-03-09 | — | — | US | claimed |
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2003-09-18 | — | — | US | claimed |
| US-10894042-B2 | Methods and pharmaceutical compositions for the treatment of cancer | Inserm (Institut National de la Santa et de la Recherche Medicale) (FR) | 2021-01-19 | — | — | US | disclosed |
| US-20190151304-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATORY | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-05-23 | — | — | US | disclosed |
| US-20190083508-A1 | USE OF OX1R ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-03-21 | — | — | US | disclosed |
| US-20090082394-A1 | Tetrahydroisoquinoline Derivatives to Enhance Memory Function | ACTELION PHARMACEUTICALS, LTD. (CH) | 2009-03-26 | — | — | US | disclosed |
| US-6703392-B2 | OREXIN RECEPTOR ANTAGONISTS FOR OBESITY OR SLEEPING DISORDER TREATMENT | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-03-09 | — | — | US | disclosed |
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082394-A1 | Tetrahydroisoquinoline Derivatives to Enhance Memory Function | GRIN2A, BDNF, GRIN2C | HCRTR1 86/4885HCRTR2 53/4885 |
| US-20190151304-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATORY | HCRTR1, HCRTR2, OXTR | HCRTR1 1/4885HCRTR2 2/4885 |
| US-10894042-B2 | Methods and pharmaceutical compositions for the treatment of cancer | OXTR, OGFR, OXGR1 | HCRTR1 18/4885HCRTR2 14/4885 |
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | HCRTR2, HCRTR1, NPY2R | HCRTR1 2/4885HCRTR2 1/4885 |
| US-20190083508-A1 | USE OF OX1R ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES | GPR180, OXGR1, MLNR | HCRTR1 22/4885HCRTR2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.